- <![CDATA[ADCs Reshape the Future of Lung Cancer Care: From Second-Line Therapy to Earlier Intervention]]><![CDATA[Judy Wang, MD, discusses how ADCs are transforming NSCLC treatment with improved responses, biomarker-driven care, and CNS activity.]]>onclive · 2mo ago↗ source
- <![CDATA[The OncFive: Top Oncology Articles for the Week of 5/3]]><![CDATA[The FDA clears zenocutuzumab in NRG1 fusion+ cholangiocarcinoma, accepts a taletrectinib NDA in ROS1+ NSCLC for review, and more.]]>onclive · 2mo ago↗ source
- <![CDATA[Dr Randall on Long-Term Responses and Functional Benefits With Pimicotinib in TGCT]]><![CDATA[R. Lor Randall, MD, FACS discusses safety and efficacy data from the MANEUVER trial, which evaluated pimicotinib in TGCT.]]>onclive